*: Significant at 0.05 significance level; ^: using Mann-Whitney U test; #: using Chi-square/Fisher exact test. IQR: interquartile range.
Declarations
Author contributions
AAA: Conceptualization, Methodology, Writing—original draft, Writing—review & editing, Data curation. KAH: Conceptualization, Methodology, Writing—original draft, Writing—review & editing, Data curation. AA: Conceptualization, Methodology, Writing—original draft, Writing—review & editing. MZ: Conceptualization, Methodology, Writing—original draft, Writing—review & editing. RKAF: Conceptualization, Methodology, Writing—original draft, Writing—review & editing, Data curation. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Ethical approval
The study was conducted in accordance with the principles outlined in the World Medical Association Declaration of Helsinki. It received approval from the JUH Institutional Review Board (approval number 10/2024/1389).
Consent to participate
To ensure patient confidentiality, all data were de-identified and anonymized. Given the retrospective, observational design, the ethical committee granted a waiver for informed consent.
Consent to publication
Not applicable.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al.; CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.N Engl J Med. 2015;373:415–27. [DOI] [PubMed] [PMC]
Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon.Pathog Glob Health. 2015;109:309–18. [DOI] [PubMed] [PMC]
Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.Antimicrob Resist Infect Control. 2018;7:98. [DOI] [PubMed] [PMC]
Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis.PLoS One. 2017;12:e0189621. [DOI] [PubMed] [PMC]
Dadgostar P. Antimicrobial Resistance: Implications and Costs.Infect Drug Resist. 2019;12:3903–10. [DOI] [PubMed] [PMC]
Chaaban T, Ezzeddine Z, Ghssein G. Antibiotic misuse during the COVID-19 pandemic in Lebanon: a cross-sectional study.COVID. 2024;4:921–9. [DOI]
Daniel Markley J, Bernard S, Bearman G, Stevens MP. De-escalating Antibiotic Use in the Inpatient Setting: Strategies, Controversies, and Challenges.Curr Infect Dis Rep. 2017;19:17. [DOI] [PubMed]
Trupka T, Fisher K, Micek ST, Juang P, Kollef MH. Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study.Crit Care. 2017;21:180. [DOI] [PubMed] [PMC]
Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front.Clin Infect Dis. 2008;47 Suppl 1:S3–13. [DOI] [PubMed]
Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, et al. A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit.Clin Infect Dis. 2016;62:1009–17. [DOI] [PubMed]
Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial Antibiotic Resistance: The Most Critical Pathogens.Pathogens. 2021;10:1310. [DOI] [PubMed] [PMC]
Nadeem SF, Gohar UF, Tahir SF, Mukhtar H, Pornpukdeewattana S, Nukthamna P, et al. Antimicrobial resistance: more than 70 years of war between humans and bacteria.Crit Rev Microbiol. 2020;46:578–99. [DOI] [PubMed]
Pitiriga V, Vrioni G, Saroglou G, Tsakris A. The Impact of Antibiotic Stewardship Programs in Combating Quinolone Resistance: A Systematic Review and Recommendations for More Efficient Interventions.Adv Ther. 2017;34:854–65. [DOI] [PubMed]
Kherroubi L, Bacon J, Rahman KM. Navigating fluoroquinolone resistance in Gram-negative bacteria: a comprehensive evaluation.JAC Antimicrob Resist. 2024;6:dlae127. [DOI] [PubMed] [PMC]
Lynch JP 3rd, File TM Jr, Zhanel GG. Levofloxacin for the treatment of community-acquired pneumonia.Expert Rev Anti Infect Ther. 2006;4:725–42. [DOI] [PubMed]
Khan AS, Iqbal A, Muhammad AA, Mazhar F, Lodhi MF, Ahmed KF, et al. Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials.Cureus. 2023;15:e37650. [DOI] [PubMed] [PMC]
Deshpande A, Richter SS, Haessler S, Lindenauer PK, Yu PC, Zilberberg MD, et al. De-escalation of Empiric Antibiotics Following Negative Cultures in Hospitalized Patients With Pneumonia: Rates and Outcomes.Clin Infect Dis. 2021;72:1314–22. [DOI] [PubMed] [PMC]
Joung MK, Lee JA, Moon SY, Cheong HS, Joo EJ, Ha YE, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia.Crit Care. 2011;15:R79. [DOI] [PubMed] [PMC]
Arnold HM, Micek ST, Skrupky LP, Kollef MH. Antibiotic stewardship in the intensive care unit.Semin Respir Crit Care Med. 2011;32:215–27. [DOI] [PubMed]
Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate.Intensive Care Med. 2007;33:1533–40. [DOI] [PubMed] [PMC]
Knaak E, Cavalieri SJ, Elsasser GN, Preheim LC, Gonitzke A, Destache CJ. Does antibiotic de-escalation for nosocomial pneumonia impact intensive care unit length of stay?Infect Dis Clin Pract. 2013;21:172–6. [DOI]
López-Cortés LE, Delgado-Valverde M, Moreno-Mellado E, Goikoetxea Aguirre J, Guio Carrión L, Blanco Vidal MJ, et al.; SIMPLIFY study group. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.Lancet Infect Dis. 2024;24:375–85. [DOI] [PubMed]
